Skip to main content
Fig. 2 | Allergy, Asthma & Clinical Immunology

Fig. 2

From: Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from Phase 2 and Phase 3 randomized, double-blind, placebo- and active-referenced studies

Fig. 2

Changes in rDNSS per day over the 2-week randomized treatment period. a Phase 2 data based on modified all-treated set) and b Phase 3 data based on modified ITT (intent-to-treat) set. Data are mean ± standard error (SE). *p values for mean changes from baseline with setipiprant vs. placebo; †p values for mean changes from baseline with cetirizine vs. placebo

Back to article page

Allergy, Asthma & Clinical Immunology

ISSN: 1710-1492

Contact us